Literature DB >> 15039337

Normally occurring human anti-GM1 immunoglobulin M antibodies and the immune response to bacteria.

María E Alaniz1, Ricardo D Lardone, Silvia L Yudowski, María I Farace, Gustavo A Nores.   

Abstract

Anti-GM(1) antibodies of the immunoglobulin M (IgM) isotype are normal components of the antibody repertoire of adult human serum. Using a sensitive high-performance thin-layer chromatography (HPTLC) immunostaining assay, we found that these antibodies were absent in the umbilical vein and children <1 month of age but could be detected after 1 month of age. Although most of the children older than 6 months of age were positive, there were still a few negative children. The appearance of anti-GM(1) IgM antibodies showed a perfect concordance with two well-characterized antibacterial antibodies, anti-Forssman and anti-blood group A, which indicates a similar origin. We also studied IgM reactivity with lipopolysaccharides (LPSs) from gram-negative bacteria isolated from stool samples from healthy babies and from Escherichia coli HB101 in serum from individuals of different ages. We found a positive reaction with both LPSs in all the children more than 1 month of age analyzed, even in those that were negative for anti-GM(1) antibodies. Anti-GM(1) IgM antibodies were purified from adult serum by affinity chromatography and tested for the ability to bind LPSs from different bacteria. This highly specific preparation showed reactivity only with LPS from a strain of Campylobacter jejuni isolated from a patient with diarrhea. We conclude that normally occurring IgM antibodies are generated after birth, probably during the immune defense against specific bacterial strains.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15039337      PMCID: PMC375194          DOI: 10.1128/IAI.72.4.2148-2151.2004

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  27 in total

1.  Anti-GM1 ganglioside IgM-antibodies present in human plasma: affinity and biological activity changes in a patient with neuropathy.

Authors:  R K Mitzutamari; L J Kremer; E A Basile; G A Nores
Journal:  J Neurosci Res       Date:  1998-01-15       Impact factor: 4.164

Review 2.  Blood-group and Forssman antigenic determinants shared between microbes and mammalian cells.

Authors:  G F Springer
Journal:  Prog Allergy       Date:  1971

3.  Sulfation of glycosphingolipids and related carbohydrates by brain preparations from young rats.

Authors:  F A Cumar; H S Barra; H J Maccioni; R Caputto
Journal:  J Biol Chem       Date:  1968-07-25       Impact factor: 5.157

4.  Anti-GM1 antibodies can block neuronal voltage-gated sodium channels.

Authors:  F Weber; R Rüdel; P Aulkemeyer; H Brinkmeier
Journal:  Muscle Nerve       Date:  2000-09       Impact factor: 3.217

5.  Variable patterns of anti-GM(1) IgM-antibody populations defined by affinity and fine specificity in patients with motor syndromes: evidence for their random origin.

Authors:  P H Lopez; R D Lardone; F J Irazoqui; A M Villa; M Di Egidio; R D Saizar; R E Sica; G A Nores
Journal:  J Neuroimmunol       Date:  2001-09-03       Impact factor: 3.478

Review 6.  The origin of anti-GM1 antibodies in neuropathies: the "binding site drift" hypothesis.

Authors:  Pablo H H Lopez; Ricardo D Lardone; Fernando J Irazoqui; Mariana Maccioni; Gustavo A Nores
Journal:  Neurochem Res       Date:  2002-08       Impact factor: 3.996

7.  Anti-GM1 IgG antibodies induce leukocyte effector functions via Fcgamma receptors.

Authors:  Nina M van Sorge; Leonard H van den Berg; Karin Geleijns; Jos A van Strijp; Bart C Jacobs; Pieter A van Doorn; John H J Wokke; Jan G J van de Winkel; Jeanette H W Leusen; W-Ludo van der Pol
Journal:  Ann Neurol       Date:  2003-05       Impact factor: 10.422

8.  High affinity as a disease determinant factor in anti-GM(1) antibodies: comparative characterization of experimentally induced vs. disease-associated antibodies.

Authors:  P H H Lopez; A M Villa; R E P Sica; G A Nores
Journal:  J Neuroimmunol       Date:  2002-07       Impact factor: 3.478

9.  Lipopolysaccharides from Campylobacter jejuni O:41 strains associated with Guillain-Barré syndrome exhibit mimicry of GM1 ganglioside.

Authors:  M M Prendergast; A J Lastovica; A P Moran
Journal:  Infect Immun       Date:  1998-08       Impact factor: 3.441

10.  Gangliosides of human, bovine, and rabbit plasma.

Authors:  R K Yu; R W Ledeen
Journal:  J Lipid Res       Date:  1972-09       Impact factor: 5.922

View more
  6 in total

Review 1.  Ganglioside molecular mimicry and its pathological roles in Guillain-Barré syndrome and related diseases.

Authors:  Robert K Yu; Seigo Usuki; Toshio Ariga
Journal:  Infect Immun       Date:  2006-09-11       Impact factor: 3.441

Review 2.  Guillain-Barré syndrome: expanding the concept of molecular mimicry.

Authors:  Jon D Laman; Ruth Huizinga; Geert-Jan Boons; Bart C Jacobs
Journal:  Trends Immunol       Date:  2022-03-04       Impact factor: 19.709

3.  No direct binding of the heat-labile enterotoxin of Escherichia coli to E. coli lipopolysaccharides.

Authors:  Lena Jansson; Jonas Angström; Michael Lebens; Susann Teneberg
Journal:  Glycoconj J       Date:  2009-10-21       Impact factor: 2.916

4.  Individual Restriction Of Fine Specificity Variability In Anti-GM1 IgG Antibodies Associated With Guillain-Barré Syndrome.

Authors:  Ricardo D Lardone; Nobuhiro Yuki; Fernando J Irazoqui; Gustavo A Nores
Journal:  Sci Rep       Date:  2016-01-28       Impact factor: 4.379

5.  Most of anti-glycolipid IgG-antibodies associated to neurological disorders occur without their IgM counterpart.

Authors:  Ricardo Dante Lardone; Fernando José Irazoqui; Gustavo Alejandro Nores
Journal:  J Biomed Sci       Date:  2019-09-06       Impact factor: 8.410

6.  Neurological disorders-associated anti-glycosphingolipid IgG-antibodies display differentially restricted IgG subclass distribution.

Authors:  Ricardo D Lardone; Fernando J Irazoqui; Gustavo A Nores
Journal:  Sci Rep       Date:  2020-08-04       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.